RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

YMN-A02 for Advanced Primary Hepatocellular Carcinoma.

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorWest China Hospital四川大学华西医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07580261, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Patients with histologically confirmed advanced primary hepatocellular carcinoma that has progressed after treatment with anti-angiogenic targeted therapy and immune checkpoint inhibitors.

    Inclusion criterion 3

  3. Age and performance status: Aged 18-70 years; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

    Inclusion criterion 2

  4. At least one target lesion with a measurable diameter according to RECIST criteria (longest diameter of tumor lesion ≥10 mm on CT scan; short diameter of lymph node lesion ≥10 mm on CT scan; slice thickness ≤5 mm).

    Inclusion criterion 4

  5. Previous or concurrent diagnosis of another malignancy, except for the following: carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, urothelial carcinoma of the bladder that has been treated with curative intent, or any other malignancy that has been treated with curative intent with no evidence of recurrence for 5 years or more.

    Exclusion criterion 2

    Presence of active infection, including but not limited to: active tuberculosis, bacterial or fungal infection requiring systemic treatment (NCI-CTCAE v5.0 Grade ≥2), human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection (HBV DNA above the upper limit of normal), or active hepatitis C virus (HCV) infection (HCV RNA above the upper limit of normal).

    Exclusion criterion 5

  6. Pregnant or breastfeeding women.

    Exclusion criterion 4

    Pregnancy plan (for female subjects or partners of male subjects) from the screening period until 12 months after the last dose.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07580261, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Informed consent: Signed informed consent form approved by the ethics committee.
  • Age and performance status: Aged 18-70 years; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • Patients with histologically confirmed advanced primary hepatocellular carcinoma that has progressed after treatment with anti-angiogenic targeted therapy and immune checkpoint inhibitors.
  • At least one target lesion with a measurable diameter according to RECIST criteria (longest diameter of tumor lesion ≥10 mm on CT scan; short diameter of lymph node lesion ≥10 mm on CT scan; slice thickness ≤5 mm).
  • Life expectancy: ≥3 months.
  • Adequate major organ function, as verified by the following laboratory and test results obtained within 14 days prior to randomization:

Hematology: Hemoglobin ≥80 g/L (no blood transfusion within 14 days); absolute neutrophil count >1.5×10⁹/L; platelet count ≥80×10⁹/L.

Biochemistry: Total bilirubin ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5×ULN; if liver metastases are present, ALT or AST ≤5×ULN; endogenous creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).

Cardiac assessment: Left ventricular ejection fraction (LVEF) ≥50% as assessed by Doppler echocardiography.

  • Good compliance and follow-up agreement: The patient is compliant and the family agrees to cooperate with survival follow-up.

Exclusion Criteria:

  • Participation in another clinical trial of an investigational drug within 4 weeks prior to enrollment.
  • Previous or concurrent diagnosis of another malignancy, except for the following: carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, urothelial carcinoma of the bladder that has been treated with curative intent, or any other malignancy that has been treated with curative intent with no evidence of recurrence for 5 years or more.
  • Presence of poorly controlled cardiac disease or clinical symptoms, including but not limited to: New York Heart Association (NYHA) Class ≥2 heart failure, unstable angina, myocardial infarction within the past year, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
  • Pregnant or breastfeeding women.
  • Presence of active infection, including but not limited to: active tuberculosis, bacterial or fungal infection requiring systemic treatment (NCI-CTCAE v5.0 Grade ≥2), human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection (HBV DNA above the upper limit of normal), or active hepatitis C virus (HCV) infection (HCV RNA above the upper limit of normal).
  • History of psychotropic substance abuse that cannot be abstained from, or history of mental disorders.
  • Presence of active autoimmune disease or history of autoimmune disease (including but not limited to: uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism, etc.). The following are exceptions: vitiligo controlled with topical medication only; childhood asthma that has completely resolved and requires no intervention in adulthood; patients with asthma requiring bronchodilators for medical intervention are not eligible.
  • Prior vaccination with any mRNA-based drug or mRNA formulation.
  • Prior participation in clinical trials involving lipid nanoparticle (LNP) formulations.
  • Contraindications to intravenous infusion.
  • History of drug abuse, or medical, psychological, or social conditions (such as history of alcoholism or drug addiction) that, in the investigator's judgment, may affect compliance with the study.
  • Known allergy, hypersensitivity, or intolerance to any component of the study formulation (including active ingredients and excipients); history of severe drug, food, or vaccine allergy, including but not limited to: anaphylactic shock, allergic laryngeal edema, allergic dyspnea, anaphylactoid purpura, thrombocytopenic purpura, or Arthus reaction.
  • Pregnancy plan (for female subjects or partners of male subjects) from the screening period until 12 months after the last dose.
  • Any concomitant disease that, in the investigator's judgment, may jeopardize patient safety or interfere with the completion of the study.

Quoted from ClinicalTrials.gov, NCT07580261, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07580261, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07580261